IN VITRO EFFECT OF ANTISENSE OLIGOMERS ON INFECTION WITH AND PRODUCTION OF MOUSE MAMMARY TUMOR VIRUS (MMTV) (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

IN VITRO EFFECT OF ANTISENSE OLIGOMERS ON INFECTION WITH AND PRODUCTION OF MOUSE MAMMARY TUMOR VIRUS (MMTV) (MEETING ABSTRACT)

FASEB J; 5(6):A1705 1991. Unique Identifier : AIDSLINE ICDB/91676500
Rucker P; Myers WL; Southern Illinois Univ. Sch. of Medicine, Springfield, IL; 62794-9230

Abstract: The use of antisense oligomers has been shown to be effective in inhibiting replication of another retrovirus, human immunodeficiency virus (HIV). The purpose of this study was to investigate antisense oligomers which may be useful in inhibiting MMTV infection and/or replication. We have synthesized five 20-mer oligomers which are complementary to the MMTV proviral DNA. The targets chosen were based on previously published work for HIV. The effect of the oligomers on reducing initial infection of a normal mouse mammary epithelial line (NMuMG) with MMTV is determined by using immunofluorescent cell staining to the GP52/36 viral membrane proteins to measure the infection centers. A chronically MMTV-infected cell line (Mm5MT) is used to determine the effect of the oligomers on viral production. At days 1, 3 and 5 after treatment of cell cultures with the various antisense oligomers, the production and release of MMTV into the media are measured by competition ELISA using an anti-GP52/36 serum. The level of reverse transcriptase activity in each culture condition is also determined daily by RDDP assay on days 1-6 after treatment. Initial results indicate that inhibition of MMTV replication by antisense oligomers is dose- and site-dependent and ranges from 20-90% for the culture condition used.

Keywords: Animal Cell Line Dose-Response Relationship, Drug Mammary Tumor Viruses, Mouse/*DRUG EFFECTS Mice Oligonucleotides, Antisense/*PHARMACOLOGY Tumor Cells, Cultured/*MICROBIOLOGY Virus Replication/*DRUG EFFECTS ABSTRACT
912130
M91C4076

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .